Tumor Associated Macrophages News and Research

RSS

MGH researchers find how metformin drug prevents progression of pancreatic cancer

Massachusetts General Hospital investigators may have uncovered a novel mechanism behind the ability of the diabetes drug metformin to inhibit the progression of pancreatic cancer.

17 Jan 2016

Novel technique may help women and their oncologists choose options for treating breast cancer

Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.

6 Oct 2015

Researchers make major step toward finding target to combat drug-resistant neuroblastoma

Researchers at Children's Hospital Los Angeles have made an important step toward finding a target in the fight against drug-resistant neuroblastoma (NBL), the most common solid malignancy found, outside of the skull, in children.

14 May 2015

Game theory and the cancer ecosystem: an interview with Professor Pienta, Johns Hopkins

The classic description of game theory was described by the prisoner's dilemma, which is a situation in which two players have two options where the outcome depends on the simultaneous choice made by the other.

29 Oct 2014

Study: CD206-targeting Manocept platform may provide potential avenues to enhance diagnosis in Kaposi Sarcoma

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators from the University of California, San Francisco (UCSF) presented results at the 2014 American Association for Cancer Research (AACR) conference, April 5-9, 2014 in San Diego, CA, highlighting the potential utility of imaging agents derived from Navidea's Manocept™ platform in identifying affected tissues and lymph nodes in patients with Kaposi Sarcoma (KS).

10 Apr 2014

Study demonstrates direct effects of fragmented sleep on tumor growth

Poor-quality sleep marked by frequent awakenings can speed cancer growth, increase tumor aggressiveness and dampen the immune system's ability to control or eradicate early cancers, according to a new study published online January 21, 2014, in the journal Cancer Research.

27 Jan 2014

Experimental drug that targets macrophages decreases cancer's growth

An experimental drug that targets macrophages, a type of immune cells, in the microenvironment surrounding the lethal brain tumor glioblastoma multiforme decreased the cancer's growth and extended survival of laboratory mice with the cancer, scientists will report on Tuesday Dec. 17, at the American Society for Cell Biology annual meeting in New Orleans.

16 Dec 2013

New mechanism explains why anti-tumor activity of specific immune suppressed during tumor growth

The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth. They have also demonstrated that blocking the protein Nrp1 can restore this anti-tumor immune response.

12 Dec 2013

Researchers explain why anti-tumor activity of specific immune cells suppress during tumor growth

The Leuven-based VIB researchers have revealed a mechanism that explains why the anti-tumor activity of specific immune cells called macrophages is suppressed during tumor growth.

10 Dec 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

Stromal cells offer chemotherapy clue in early lung cancer

Podoplanin-positive cancer-associated fibroblasts predict recurrence in stage I lung adenocarcinoma, which could help identify patients suited for adjuvant chemotherapy, research shows.

24 Jul 2012

Advanced papillary thyroid cancer patients with BRAFV600E gene mutation at higher risk

Individuals with advanced papillary thyroid cancer (PTC) that are associated with the BRAFV600E gene mutation have a higher risk of recurrent disease and progression to more advanced, poorly differentiated thyroid cancer, according to data presented today at the 81st Annual Meeting of the American Thyroid Association (ATA).

28 Oct 2011

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Plexxikon today announced that it has treated the first patient in a Phase 2 clinical trial in Hodgkin lymphoma with PLX3397. This novel agent is an oral, selective inhibitor that down-modulates two key cell types that are thought to mediate the progression of Hodgkin lymphoma tumors — macrophages and mast cells.

8 Mar 2011

HRG protein inhibits tumor growth and metastasis: Study

Most cancer tissues are invaded by inflammatory cells that either stimulate or inhibit the growth of the tumor, depending on what immune cells are involved. Now a Swedish-Belgian research team has shown that a protein that naturally occurs in the body, HRG, inhibits tumor growth and metastasis into secondary organs by activating specific immune cells.

7 Jan 2011

Study shows breast inflammation promotes development and progression of cancer

It took 12 years and a creation of a highly sophisticated transgenic mouse, but researchers at Kimmel Cancer Center at Jefferson have finally proven a long suspected theory: Inflammation in the breast is key to the development and progression of breast cancer.

15 Dec 2010

hBD-3 biomarker helps early stage detection of oral cancer

Detecting oral cancer in its earliest stages can save the lives of the nearly 40,500 people diagnosed annually. But early detection has been difficult. Case Western Reserve University School of Dental Medicine researchers discovered a biomarker, called human beta defensin-3 (hBD-3), which may serve as an early warning. The defensin is present in all oral cancers and associated with the early stages of oral cancer.

23 Jul 2010

Medical standard of care triggers biological responses in brain that can fuel tumor cell survival: Researchers

The medical standard of care - comprised of surgery, radiation and chemotherapy - for the most common form of brain cancer triggers a number of biological responses that may actually feed the energy metabolism that supports the disease, according to Boston College researchers writing in the journal Lancet Oncology.

15 Jul 2010